12:00 AM
 | 
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Byetta exenatide regulatory update

EMA's CHMP issued a positive opinion to expand the label for Byetta exenatide to include add-on therapy to basal insulin to treat Type II diabetes in patients who...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >